SpringWorks Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference
SpringWorks Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference
SpringWorks is a commercial-stage biopharmaceutical company applying a precision medicine approach to developing and delivering life-changing medicines for people with severe rare diseases and cancer. OGSIVEO (nirogacestat), approved in the United States for the treatment of adult patients with progressing desmoid tumors who require systemic treatment, is the Company's first FDA-approved therapy. SpringWorks also has a diversified targeted therapy pipeline spanning solid tumors and hematological cancers, with programs ranging from preclinical development through advanced clinical trials. In addition to its wholly owned programs, SpringWorks has also entered into multiple collaborations with innovators in industry and academia to unlock the full potential for its portfolio and create more solutions for patients in need.STAMFORD, Conn., Nov. 26, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that management will participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference, taking place in Coral Gables, Florida on Tuesday, December 3, 2024 at 12:30 p.m. ET.
康涅狄格州斯坦福，2024年11月26日（環球新聞）-- springworks therapeutics公司（納斯達克：SWTX），是一家專注於重度罕見病和癌症的商業階段生物製藥公司，今天宣佈管理層將參加於2024年12月3日星期二東部時間下午12:30在佛羅里達州科拉爾蓋布爾舉行的第七屆evercore ISI健康大會上的爐邊聊天。
To access the live webcast, please visit the Events & Presentations page within the Investors & Media section of the company's website at . A replay of the webcast will be available on SpringWorks' website for a limited time following the conference.
要查看現場網絡直播，請訪問該公司網站的投資者與媒體部分的活動與展示頁面。在會後一段時間內，您可以在SpringWorks的網站上找到網絡直播的重播。
About SpringWorks Therapeutics
關於springworks therapeutics
SpringWorks is a commercial-stage biopharmaceutical company applying a precision medicine approach to developing and delivering life-changing medicines for people with severe rare diseases and cancer. OGSIVEO (nirogacestat), approved in the United States for the treatment of adult patients with progressing desmoid tumors who require systemic treatment, is the Company's first FDA-approved therapy. SpringWorks also has a diversified targeted therapy pipeline spanning solid tumors and hematological cancers, with programs ranging from preclinical development through advanced clinical trials. In addition to its wholly owned programs, SpringWorks has also entered into multiple collaborations with innovators in industry and academia to unlock the full potential for its portfolio and create more solutions for patients in need.
springworks是一家商業化生物製藥公司，採用精準醫學方法開發和提供改變生活的藥物，用於罕見疾病和癌症患者。 在美國獲批用於治療需要全身治療的進展性腱狀腫瘤成人患者的OGSIVEO（nirogacestat）是該公司首個獲得FDA批准的療法。 springworks還擁有涵蓋實體腫瘤和血液系統癌症的多樣化靶向療法管線，涵蓋了從臨床前開發到愛文思控股臨床試驗的項目。 除了其全資項目外，springworks還與行業和學術界創新者達成多項合作，以釋放其投資組合的全部潛力，併爲有需要的患者提供更多解決方案。
For more information, visit and follow @SpringWorksTx on X (formerly Twitter), LinkedIn, and YouTube.
要獲取更多信息，請訪問 並關注@SpringWorksTx@springworks therapeutics 在X（前身爲Twitter） LinkedIn，和 YouTube.
Contacts:
Investors
investors@springworkstx.com
聯繫人：
投資者
investors@springworkstx.com
Media
media@springworkstx.com
媒體
media@springworkstx.com
譯文內容由第三人軟體翻譯。
